Previous close | 2.2100 |
Open | 2.2001 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 2.0800 - 2.2001 |
52-week range | 0.9600 - 3.8500 |
Volume | |
Avg. volume | 37,096 |
Market cap | 50.218M |
Beta (5Y monthly) | 0.89 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.8200 |
Earnings date | 14 May 2024 - 20 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.50 |
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentation at the 23rd Annual Needham Virtual Healthcare Conference, which is being held April 8-11, 2024. Presentation details: Date:Wednesday, April 10th Time:8:00-8:40 AM ET Webcast:https://wsw.com/webcast/needham13
It hasn't been the best quarter for InspireMD, Inc. ( NASDAQ:NSPR ) shareholders, since the share price has fallen 16...
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of the CGuard™ Prime Carotid Stent System for the treatment of carotid artery stenosis has been accepted for presentation at the Leipzig Interventional Course (LINC) 2024, which is being held May 28-31, in Leipzig,